As the midterm elections loom, politicians are trotting out their stump speeches promising, among other things, to lower the cost of prescription drugs. We’ve been hearing these kinds of promises for years, with few results.

If members of Congress really want to get serious about tackling the mounting cost of medications, they need to start by doing two simple things:

  • Stop relying on drug companies for information about medication
  • Hire more policy staffers who can go head to head with big pharma

Creating a permanent commission to advise Congress on drug policy accomplishes both goals.

advertisement

Instead of taking even basic steps to counteract the pharmaceutical industry and its lobbyists, Congress has made itself more vulnerable to industry predation. Over the past 25 years, Congress has repeatedly cut its own funding for staff and now lacks the staff needed for sustained oversight and sophisticated legislating.

Instead, Congress is forced to turn to outside sources, which inevitably include industry lobbyists, to help it draft and analyze legislation. Like a fox building the henhouse, drug companies act in their own self-interest, opposing real reform while feeding Congress ideas that line drug company’s pockets.

Even if Congress can’t stop drug companies — or any other businesses — from flooding it with donations, it needs to stop relying on the pharmaceutical industry for its drug policy ideas. To do this, Congress should consolidate and strengthen the legislative process by creating and maintaining a permanent advisory commission on drug policy. Comprising a dozen or so experts chosen by the nonpartisan Government Accountability Office, this commission would publicly examine the prescription drug problems facing patients, pharmacies, doctors, hospitals, pharmacy benefit managers, and even drug manufacturers themselves.

The commission would be able to contribute a comprehensive vision of drug policy that Congress, with its fragmented committee system, sorely lacks. While the House and Senate each have four committees responsible for regulating discrete aspects of the pharmaceutical industry, no one in Congress has the job of understanding how different laws interact and contribute to the generation of high prices.

By contrast, drug companies have centralized operations and understand every facet of their business and the Byzantine regulations that govern it. A drug pricing commission would let Congress break down its informational siloes and match big pharma’s global perspective.

A commission could also comment on rules proposed by the FDA, the Centers for Medicare and Medicaid Services, and other relevant government agencies. That would help Congress keep track of how its laws are implemented while protecting executive agencies from being captured by interest groups. This commission would conclude its annual deliberations with a set of recommendations in an annual report to Congress.

Newsletters

Sign up for our D.C. Diagnosis newsletter

Please enter a valid email address.

Unlike blue-ribbon commissions that come and go with much acclaim and few accomplishments, a permanent commission can liberate Congress from its dependence on industry expertise. Grounded in evidence, the commission’s reports would provide Congress with clear analyses and carefully constructed solutions. Instead of starting with industry proposals, Congress could instead begin the legislative process by focusing on the needs of the many, not the profits of a few.

After the past eight years of partisan squabbling over the Affordable Care Act, this may sound hopelessly naive. But it isn’t. For more than 20 years, Congress has relied on a nonpartisan commission of experts to advise it on Medicare policy: the Medicare Payment Advisory Commission (MedPAC). Its recommendations are carefully evaluated by members of Congress — Democratic and Republican alike. Indeed, its recommendations have served as the blueprint for the last decade of Medicare reforms, successfully pushing Congress to pass laws that reward the quality of care instead of the quantity of care. Similarly, at MedPAC’s urging, Congress stopped giving raises to providers who weren’t becoming more productive. Because of MedPAC, when Congress crafts Medicare policy, it isn’t beholden to industry groups for expert information and analysis.

Congress has promised to fix drug prices several times before, yet the problem has only intensified. Congress needs to cure the process before it can cut prices. A prescription drug commission is just the medicine Congress needs.

Scott Levy is a former staffer for the Senate Finance Committee and a recent graduate of Yale Law School.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Another silly good idea. Who knew that putting industry insiders on government regulatory boards, and encouraging unlimited cash donations to policy makers could kill Americans. This is a naive idea, since the facts have been effectively censored. Congress was told that Data collection was “Government Overreach” by well funded corporate lobbyists. No one in Congress know how many people died last year, either because of the cost or the lack of effectiveness of these pharma products. Pharma ensured that no one would know, they made the information propitiatory. Even Physician are not allowed to keep track of any data regarding the drugs they prescribe. The lack of data is by design, and goes unmentioned, it is a secret.
    No commission would have access to factual data, they would be on about the same level as American healthcare “Consumers” completely in the dark, except for pharma advertising and publications like this. No journalsi here has mentioned how little data they are able to get, they did not noticed or where persuaded to avoid the subject. The Industry lobbyists in the meantime, and complicit journalists have been peddling the idea of a data revolution. The only data collected anymore is the data, on profitability and misleading the public. Wake up people!

  • We don’t need anymore government non-doctors. People who make physicians into outlaw drug dealers for prescribing pain medicine to documented, proven pain patients. We need doctors who have gone through pain themselves, that understand what life is like without any relief. Someone who knows how debilitating it is mentally and physically to endure pain 24/7 with no effective relief. A doctor who has had their quality of life dictated by someone who doesn’t know or care what it is like. We need doctors who will stand behind their patients, not wait for the government to tell him how to do his job. We don’t need dictators telling us how to live, or wait to die a slow painful death. A real doctor is supposed to cause no harm. Ignoring patients pain and inventing excuses to refuse help, causes harm. Politicians should stay out of a documented, proven pain patients care. They are causing millions to suffer needlessly.

  • “Congress should consolidate and strengthen the legislative process by creating and maintaining a permanent advisory commission on drug policy.”

    why limit the commission to drug policy? if you’re sincere about decreasing healthcare costs, look at health insurers, IDNs and PBMs as well.

  • If you really want to address the cost of prescription drugs: a) work on lowering the cost to get a cure to the market and b) provide a reasonable period for the company recover their investment and provide a reasonable return to investors. As long as we expect companies to spend billions and let generics take away the market in as little as 5 years, they will continue to act as they do.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy